Skip to content

Ayurvedic management of Asrugdara (Abnormal Uterine Bleeding) in Perimenopausal Women

Efficacy of Vasa-Guduchyadi Ghanavati and Nyagrodhadi Gana Ghanavati in the management of Asrugdara W.S.R. to Endometrial Hyperplasia in perimenopausal women- A Single Arm open labeled clinical trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065979
Enrollment
20
Registered
2024-04-19
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N924- Excessive bleeding in the premenopausal period

Interventions

None listed

Sponsors

Institute of Teaching and Research in Ayurveda Jamnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having chief complaint of regular/irregular menstrual cycle with bleeding more than 7days and/or PBAC Score more than 100. Females of age group between 40 to 55 yrs. Women with Hb more than or equal to 8 gm percent On USG (TVS/Abd), hyperplasia of endometrium- The cut-off values for perimenopausal women will be (endometrial thickness) more than or equal to 8 mm on 8th to 11th day of menstrual cycle. If the patients had their last menstruation within 12 months but forgot their exact last menstrual period (LMP) or could not expect their next menstruation date, then cut-off value will be more than or equal to 8 mm.

Exclusion criteria

Exclusion criteria: Patient age of less than 40 years and more than 55 years. Women with Hb less than 8gm percent. K/C of Bleeding disorders like Hemophilia, Von Willebrand disease, Thrombocytopinia. Congenital anomaly of reproductive tract. Known Patients of cervical polyp, endometriosis, tubo-ovarian mass, pelvic inflammatory diseases and endometrial cancer. Suffering from chronic systemic diseases like, uncontrolled hypertension (Systolic blood pressure above 160 & Diastolic blood pressure above 100 mmhg), uncontrolled diabetes (above the range of 160 to 200 mg/dl (RBS). Patient not willing to participate.

Design outcomes

Primary

MeasureTime frame
To assess the efficacy of trial drugs in reducing the amount and duration of menstrual blood loss. To assess the efficacy of trial drugs in reducing the endometrial thickness.Timepoint: 90 days

Secondary

MeasureTime frame
Improvement in quality of lifeTimepoint: 90 days

Countries

India

Contacts

Public ContactDr Neha Pandya

Institute of Teaching and Research in Ayurveda, Jamnagar

drneha1973@yahoo.in9925650307

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026